id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_gku75b5tsjgjdltvzlc5gnrzjm	Sam Schulman	Recent Advances in Thrombosis and Hemostasis—Part IV	2019.0	2	.pdf	application/pdf	1694	206	60	new oral anticoagulants that increasingly are replacing vitamin K antagonists. the risk of deep vein thrombosis in patients infected by HIV For patients with autoimmune disease and a VTE event, a common question is how long the Borjas-Howard et al have here performed a systematic literature review to help us find some answers.3 risk of bleeding and other complications shortly after discharge from hospital among patients started on anticoagulation. to the question how NOACs perform in patients with atrial with increased risk of bleeding on the NOAC, driven by Nonvitamin K antagonist oral anticoagulants (NOACs): no longer new Risk of recurrent venous thromboembolism in autoimmune diseases: a systematic review of the literature. To maintain or cease nonvitamin K antagonist oral anticoagulants prior to minimal bleeding risk procedures: a review of evidence and recommendations. Atrial fibrillation and malignancy: the clinical performance of non-vitamin k oral anticoagulants a systematic review.	./cache/work_gku75b5tsjgjdltvzlc5gnrzjm.pdf	./txt/work_gku75b5tsjgjdltvzlc5gnrzjm.txt